FIELD: medicine; pharmacology.
SUBSTANCE: invention concerns medical product for metabolic regulation associated with magnesium deficiency in organism. Medical product is solid dosage form containing magnesium di-(L-asparaginate) in amount 200 to 1000 mg and pyridoxine hydrochloride in amount 2 to 20 mg per unit dose (magnesium di-(L-asparaginate) and pyridoxine hydrochloride in weight ratio 50:1 to 200:1).
EFFECT: medical product provides high ion bioavailability and decreased excretory system burden.
8 cl, 5 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION AND KIT WITH ANXIOLYTIC ACTION | 2017 |
|
RU2703729C2 |
| BIOLOGIALLY ACTIVE AGENT HAVING EFFECT ON GENERAL METABOLIC, EXCITATORY AND INHIBITORY NERVE FUNCTION AND INTELLECTUAL MNESTIC CEREBRAL FUNCTIONS (VERSIONS) | 2011 |
|
RU2461374C1 |
| POLYVITAMIN KIT FOR WOMEN | 2010 |
|
RU2443422C2 |
| PHARMACEUTICAL NEUROPROTECTIVE, ANTIOXIDANT, ANTIHYPOXIC, ANTIAPOPTOTIC AND MEMBRANE PROTECTIVE COMPOSITION AND METHOD OF TREATMENT | 2008 |
|
RU2385722C1 |
| METHOD FOR OBTAINING A HIGHLY DIGESTIBLE ELEMENT-BALANCED POLYCOMPONENT PREPARATION BASED ON COLLOIDAL CHELATE COMPLEXES OF ESSENTIAL TRACE ELEMENTS OF ZINC, MANGANESE, IRON, COPPER AND COBALT | 2021 |
|
RU2778509C1 |
| COMPOSITE REGULATING METABOLIC PROCESSES AND METHOD FOR ITS PREPARING | 2004 |
|
RU2278667C2 |
| ANTIOXIDANT PREPARATION FOR TREATING AND PREVENTING NEUROLOGICAL PATHOLOGIES IN ANIMALS | 2023 |
|
RU2813928C1 |
| MEDICINAL AGENT "ASPARKAM-1" FOR REGULATION OF METABOLIC PROCESSES AND METHOD FOR ITS PREPARING | 2003 |
|
RU2229879C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF MENOPAUSE OSTEOPOROSIS IN WOMEN | 2007 |
|
RU2379043C2 |
| VITAMINS-CONTAINING SYRUP FOR NON-ADULTS | 2004 |
|
RU2369271C2 |
